Response to ‘Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer’

The authors thank Yamakazi et al for their interest in our article and for raising several interesting and relevant questions regarding our findings. We agree that it is possible a lower total biological effective dose (BED) was responsible for the lower biochemical progression free survival (PFS) observed for patients treated with high dose rate brachytherapy (HDR) boost especially for the 17 Gy in 2 fractions schedule. An indication of this...